HELP Cybin Inc.
Company Analysis
Latest News
🟢 Cybin is trading 7.6% up today after Michael Halstead became CEO
Cybin is trading 7.6% up at $11.33, extending gains after Michael Halstead became chief executive officer effective immediately. - Halstead previously led...
🟢 Cybin is trading 10.1% up today as investors extend CEO appointment rally
Cybin is trading 10.1% up today at $10.22 as the stock continues to rally following the appointment of former Intra-Cellular Therapies president Michael...
🟢 Cybin is trading 11% up today after appointing former Intra-Cellular president Michael Halstead as CEO
Cybin is trading 11% up at $8.88 following the announcement of Michael Halstead as its new CEO. • Halstead previously served as the president of...
Cybin Names Michael Halstead CEO, Architect of $14.6B J&J Deal
Cybin Inc., operating as Helus Pharma (Nasdaq: HELP), appointed Michael Halstead as Chief Executive Officer, effective immediately. Halstead previously served...
Wells Fargo initiates Helus Pharma at overweight, citing depression drug potential
Wells Fargo initiated coverage of Helus Pharma (HELP) with an Overweight rating. The bank set a $16 price target for the biotechnology firm. This target...
🟢 Cybin is trading 10.2% up today amid a broad risk-on market rally
Cybin is trading at $8.40 (+10.24%) in pre-market as higher-beta names benefit from a broad risk-on move across U.S. markets. • The stock is tracking a wider...
🟢 Cybin is trading 6.3% up today on broader risk-on sentiment
Cybin is trading at $8.10 (+6.3%) in pre-market, rebounding after a weak close at $7.62 on July 24. • The move appears aligned with stronger U.S. futures and...
🟢 Cybin is trading 10.1% up
Cybin is trading at $7.83, up 10.1% from a comparison close of $7.11 during regular trading. This is a price-action follow-up, so a separate catalyst may not...
🟢 Cybin is trading 8.6% up today on Phase 3 trial progress and $50M equity raise
Cybin is trading at $7.72 (+8.58%) following fresh momentum around its late-stage depression program and a successful capital raise. • The APPROACH Phase 3...
🟢 Cybin is trading 6.6% up today on Phase 3 depression trial progress and $50M equity raise
Cybin is trading 6.6% up at $7.58 in pre-market, extending gains driven by optimism around its late-stage depression program. • The company surpassed 86%...
🟢 Cybin is trading 5.4% up today on Phase 3 progress and reinforced cash position
Cybin is trading 5.4% up at $7.64 in pre-market, extending last week’s strong gains as investors react to positive clinical developments and a strengthened...
Cybin Jumps 8% on Wall Street Cheerleading, but Can a Pre-Revenue Psychedelic Biotech Justify a $38 Price Target?
Shares shifted as Cybin Inc. — now operating as Helus Pharma (HELP) — surged 7.8% to $7.02 on bullish analyst coverage emphasizing the company's cash reserves...
🟢 Cybin is trading 12.4% up
Cybin is trading at $7.32, up 12.4% from a comparison close of $6.51 during regular trading. This is a price-action follow-up, so a separate catalyst may not...
🟢 Cybin is trading 8% up today on bullish analyst coverage and cash-position optimism
Cybin is trading 8% up today at $7.02 following upbeat analyst commentary and growing optimism regarding its cash position. • Analysts have issued multiple...
🟢 Cybin is trading 12.4% up today on bullish analyst coverage and a reinforced balance sheet
Cybin is trading 12.4% up at $7.32 in pre-market following bullish analyst coverage and commentary regarding its strengthened cash position. • Analysts cited...
🟢 Cybin is trading 9.8% up today on bullish analyst coverage and reinforced balance sheet
Cybin is trading at $7.15 (9.8%) up in pre-market following bullish analyst coverage and commentary regarding its reinforced balance sheet. • Analysts...
🟢 Cybin is trading 4.6% up today on bullish analyst coverage and a reinforced balance sheet
Cybin is trading 4.6% up at $6.81 following positive analyst sentiment and reports of a reinforced balance sheet. • Analysts highlighted clinical progress and...
🟢 Cybin is trading 12.1% up today on bullish analyst coverage and reinforced balance sheet
Cybin is trading 12.1% up at $7.30 in pre-market, extending recent strength driven by upbeat analyst coverage and a reinforced balance sheet. • Guggenheim...
🔴 Cybin is trading 5.2% down today amid a broader biotech pullback and risk-off market sentiment
Cybin is trading at $6.51 (-5.23%) as the stock faces pressure from a broader biotech sector selloff and a weaker overall market tone. • The decline aligns...
🟢 Cybin is trading 5.5% up today as it extends its multi-day rally
Cybin is trading 5.5% up at $6.57 as the stock extends its recent multi-day rally despite a lack of fresh company-specific news. • The upward move appears...